
Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within two years of patients stopping their treatment.
According to a study published in the BMJ, data from 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss drugs showed that they regained about one pound on average after stopping the drugs.
The same study said they were projected to return to their pre-treatment weight in about two years.
But weight was not the only thing that was projected to return after stopping the treatment. According to the same study, health risk factors like blood pressure and cholesterol levels, which saw benefits while taking the drugs, were projected to return to their old levels within 1.4 years.
GLP-1 medications tested as well
About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound. According to the study, the weight regain rate was faster for these drugs, with an average of 1.8 pounds per month.
“But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters.
Weight loss drugs have shown some success
Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years. Back in October 2025, a survey from the Gallup National Health and Well-Being Index showed that there were an estimated 7.6 million fewer obese people in the United States compared to 2022.
In 2022, the U.S. adult obesity rate was a record-high 39.9%, while in 2025, that rate gradually declined to 37%. While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study.
Contributing: Nicole Fallert, USA TODAY; Reuters
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at [email protected] and follow him on X @fern_cerv_.
This article originally appeared on USA TODAY: Here's how fast you can gain weight after ending GLP-1, per study
LATEST POSTS
- 1
Indoor Drinking Fountains: Famous Home Advancements during the Pandemic - 2
Which Startup's Innovation Could Reform Medical care? - 3
Vote In favor of Your Favored Web-based Book Retailor - 4
Germany's first Omani LNG shipments arrive despite Middle East disruptions - 5
The Force of Organic product: 10 Assortments That Improve Your Wellbeing
MEPs urge Commission leaders to stop Russia from returning to the Venice Biennale
Vote In favor of Your Favored Shimmering Water
It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
Teen drug use remains low, but survey finds small rise in heroin and cocaine use
Remain Cool and Solid: Top Summer Food sources for 2024
The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China
Favored Chinese Dish: Make Your Determination
Medtronic has 'significant firepower' for multiple acquisitions, executives say
Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.













